Cellular oxygen consumption in patients with diabetic ketoacidosis Authors: Jacob Vine, John H Lee, Lakshman Balaji, Anne V Grossestreuer, Andrea Morton, Natia Peradze, Nivedha Antony, Noa Berlin, Max S Kravitz, Shannon B Leland, Katherine Berg, Ari Moskowitz, Michael W Donnino, Xiaowen Liu Published: 2024 ABSTRACT AbstractBackgroundDiabetic ketoacidosis (DKA) is a potentially life-threatening disorder associated with severe alterations in metabolism and acid–base status. Mitochondrial dysfunction is associated with diabetes and its complications. Thiamine and coenzyme Q10 (CoQ10) are important factors in aerobic metabolism. In this study, we measured cellular oxygen consumption rates (OCRs) and the effects of in vitro administration of thiamine and CoQ10 on OCRs in patients with DKA versus healthy controls.MethodsBlood samples were collected from a prospective cohort of patients with DKA and from controls. Cellular OCRs were measured in peripheral blood mononuclear cells (PBMC) without treatment and after treatment with thiamine, CoQ10, or both. The mitochondrial profile was measured using an XFe96 Extracellular Flux Analyzer and XF Cell Mito Stress Test Kit (Seahorse Bioscience). A linear quantile mixed model was used to compare OCRs and estimate treatment effects.ResultsA total of 62 patients with DKA and 48 controls were included in the study. The median basal and maximal OCRs were lower in the DKA group than in the control group (basal: 4.7 [IQR: 3.3, 7.9] vs. 7.9 [5.0, 9.5], p = 0.036; maximal: 16.4 [9.5, 28.1] vs. 31.5 [20.6, 46.0] pmol/min/µg protein, p < 0.001). In DKA samples, basal and maximal OCRs were significantly increased when treated with thiamine, CoQ10, or both. In controls, basal and maximal OCR were significantly increased only with thiamine treatment.ConclusionMitochondrial metabolic profiles of patients with DKA demonstrated lower cellular oxygen consumption when compared to healthy controls. Oxygen consumption increased significantly in cells of patients with DKA treated with thiamine or CoQ10. These results suggest that thiamine and CoQ10 could potentially have therapeutic benefits in DKA via their metabolic effects on mitochondrial cellular respiration.Keywords: Diabetes, Diabetic ketoacidosis, Mitochondria, Thiamine, Coenzyme Q10, CoQ10 Background Diabetic ketoacidosis (DKA) is a potentially life-threatening disorder associated with profound alterations in metabolism and acid–base status. Even after recovering from the acute illness, it can be associated with significant morbidity and an increased risk of long-term health issues [1]. Mitochondrial dysfunction has been associated with complications of diabetes, and decreased pyruvate dehydrogenase (PDH) activity has been demonstrated in patients with DKA [2–4]. Thiamine (vitamin B1) is an essential cofactor for PDH and alpha-ketoglutarate dehydrogenase, enzymes required for the process of aerobic metabolism. A deficiency in thiamine directly results in impairment of aerobic metabolism [5, 6]. Severe thiamine deficiency can result in Beriberi disease with cardiovascular collapse, encephalopathy, severe lactic acidosis, and potentially death [7, 8]. Previous studies have shown that thiamine is often depleted in patients with diabetes, potentially contributing to morbidity associated with DKA [9–11]. For example, in a study from 2014, Moskowitz et al. found that 25% of patients with DKA were thiamine deficient, and the deficiency was associated with increased severity of lactic acidosis, potentially caused by impaired aerobic metabolism in these patients [11]. Coenzyme Q10 (CoQ10) is a fat-soluble molecule and antioxidant that has a key role in the electron transport chain [12]. Previous studies have found alterations in the concentration and functionality of CoQ10 in diabetic states, potentially contributing to its pathogenesis, and exogenous supplementation of CoQ10 in patients with diabetes has been proposed to alleviate oxidative stress, restore mitochondrial function, and improve glycemic control [13, 14]. Given that both thiamine and CoQ10 play important roles in aerobic metabolism and prior studies demonstrating mitochondrial dysfunction in diabetes and its complications, we hypothesized that 1) aerobic respiration in peripheral mononuclear cells (PBMCs) from patients with DKA will be lower than that in healthy controls and 2) supplementation with thiamine and/or CoQ10 will improve aerobic respiration. To assess this, we measured cellular oxygen consumption rates (OCRs) in PBMCs from patients with DKA and healthy controls using an XFe96 Extracellular Flux Analyzer and XF Cell Mito Stress Test Kit (Seahorse Bioscience, North Billerica, Massachusetts, USA). First, we compared the OCRs of the DKA patients and healthy controls at baseline. Second, we compared the OCRs after the PBMCs received in vitro supplementation with thiamine and CoQ10. Methods Design and setting This was a prospective observational study on patients enrolled in the Thiamine as Adjunctive Therapy in Diabetic Ketoacidosis Trial (DKAT) (NCT03717896) [15]. Patients were admitted with DKA after presenting to the Emergency Department (ED) of Beth Israel Deaconess Medical Center (BIDMC), an urban tertiary care center in Boston, Massachusetts, USA, between December 2018 and March 2023. Healthy controls were enrolled at the same time as the DKAT patients. Further details regarding the clinical trial can be found elsewhere [15]. This observational study utilized blood samples included at time of enrollment in the parent trial, before any study drug was administered. The study was approved by the local institutional review board (IRB) (protocol no. 2018P000475), and written informed consent was obtained from each patient prior to enrollment. Study population Adult patients (age ≥ 18 years) who presented to the ED and were diagnosed with DKA (defined by bicarbonate ≤ 15 mEq/L, anion gap > 12 mEq/L, pH ≤ 7.24, and urine or serum ketones ≥ 3 mmol/L) were included and enrolled within six hours of presentation [15]. Patients who received thiamine supplementation prior to enrollment; had a competing cause of severe acidosis (i.e., seizures, carbon monoxide poisoning, cyanide toxicity, or cardiac arrest); had a known allergy to thiamine; had contraindications to thiamine as determined by the clinical team; were a member of a research-protected population; and those who arrived with a do-not-resuscitate status were excluded. The control group included healthy individuals without any acute illnesses. Controls and DKA patients were enrolled concurrently to allow for simultaneous running of the mitochondrial test and minimization of measurement error. Therefore, many of the controls consisted of emergency department staff and providers and a control individual was allowed to be enrolled more than once at different time points. Data collection and blood samples Baseline demographic data and laboratory values were collected by trained research assistants and entered into a secure online database [16]. Data items included demographics, medical history, and laboratory values. Blood samples were collected upon enrollment into the study prior to study-drug administration. Fresh whole blood was used to isolate PBMCs to measure the cellular OCR. Mitochondrial function analysis PBMCs were isolated from fresh whole blood samples using the following method. Plasma was separated by centrifugation at 800 g for 15 min at 4 °C and saved without disturbing the buffy coat. Plasma was then replaced with the same volume of Roswell Park Memorial Institute Medium (RPMI), and the cell pellets were mixed by gently pipetting up and down several times to disperse the cells. PBMCs were then isolated from the RPMI substituted blood samples using a density gradient separation method according to the manufacture’s instruction (Ficoll-Paque premium; GE Healthcare Bio-Science Corporation, Piscataway, New Jersey, USA). The PBMCs were divided into four groups: (1) no treatment, (2) treatment with thiamine (0.5 μg/mL), (3) treatment with ubiquinol (reduced Coenzyme Q10, (CoQ10) (1 µg/mL), and (4) treatment with a combination of both thiamine and CoQ10. The dosing of thiamine and CoQ10, as well as the details of the experimental design, were based on our previous studies [17, 18]. The mitochondrial profile was measured using an XFe96 Extracellular Flux Analyzer and XF Cell Mito Stress Test Kit (Seahorse Bioscience, North Billerica, Massachusetts, USA). The XF Cell Mito Stress Test uses modulators of respiration that target components of the electron transport chain to measure key parameters of metabolic function. Oligomycin, carbonyl (cyanide-4-trifluoromethoxy) phenylhydrazone (FCCP), and a mix of rotenone and antimycin A were sequentially injected to inhibit specific components of the electron transport chain and provide isolated measurements of OCR for basal, maximal, ATP-linked, and non-mitochondrial respiration. From these measurements, spare respiratory capacity and proton-leaked respiration were calculated. The reported OCRs are in pmol/min/μg of protein. The protein amount was measured using the bicinchoninic acid (BCA) assay after lysing the cells. The experiment protocol followed the recommendations of the instrumentation company. Additional details regarding the instrument have been described elsewhere [17–19]. Statistical analysis Statistical analyses were performed using R software (R version 4.1.1) [20]. Baseline characteristics of categorical variables are presented as counts and proportions. For continuous variables, medians and interquartile ranges or means and standard deviations were used as appropriate based on the distribution of the data. The outcome OCR variables were summarized for each group and treatment using raw medians and interquartile ranges. To assess median differences, linear quantile mixed models (LQMM, Geraci 2014) [21] were used with a compound symmetry structure to account for within-patient clustering (as some samples originated from the same control enrolled at different times). We assessed (1) the median differences between DKA patients and healthy controls at baseline (without treatment), (2) the relative median differences between no treatment and treatment within each group, and (3) the effects of treatment in the DKA group compared to the same effect in the control group. For the first assessment, the LQMM included a single term for the group as the predictor variable, while for the latter two assessments, the LQMM included an interaction term between the group and treatment. In all models, the effect of age was controlled for by adding the logarithm of age as a covariate, given the potential effect of age on OCR. The relative median differences in OCR values for a given treatment were expressed as a proportion of the value at baseline (no treatment). Statistical significance was a priori set at p < 0.05. Results A total of 110 patients (with 62 DKA patients and 48 healthy controls) were included in the study. The baseline characteristics of the study participants are summarized in Table 1. Table 1Baseline characteristicsCharacteristicDKA (n = 62)Controls (n = 48) Age (years, median, IQR)a45 (27, 58)24 (23, 28)Male (n, %)33 (53.2)10 (20.8)Race (n, %)WhiteBlackAsianOtherUnknown37 (59.7)18 (29.0)3 (4.8)1 (1.6)3 (4.8)42 (87.5)1 (2.1)1 (2.1)3 (6.3)1 (2.1)Ethnicity (n, %)Not HispanicHispanicUnknown51 (82.3)6 (9.7)5 (8.1)38 (79.2)8 (16.7)2 (4.2) Diabetes (n, %)62 (100)2 (4.2)Type IType IIType III51 (80.6)10 (14.5)1 (4.8)2 (4.2)00DKA history (n, %)bPrevious DKANo previous DKAUnknown30 (48.4)29 (46.8)3 (4.8)––2 (4.2)Other past medical history (n, %)cCAD5 (8.1)0 (0.0)Cancer5 (8.1)1 (2.2)CHF2 (3.2)0 (0.0)COPD0 (0.0)1 (2.2)Alcohol use disorder0 (0.0)1 (2.2)HIV/AIDS1 (1.6)0 (0.0)Liver Disease0 (0.0)0 (0.0)CKD6 (9.7)0 (0.0)Stroke/TIA1 (1.6)0 (0.0)History of tobacco use5 (8.1)0 (0.0)Transplant/immunocompromised0 (0.0)0 (0.0)aAge missing for one control patient. bDiabetic ketoacidosis history unavailable for control patients. cPast medical history missing for one control patient. BMI body mass index, DKA diabetic ketoacidosis, CAD coronary artery disease, CHF congestive heart failure, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, AIDS acquired immunodeficiency syndrome, TIA transient ischemic attack, SOFA sequential organ failure assessment Baseline characteristics White Black Asian Other Unknown 37 (59.7) 18 (29.0) 3 (4.8) 1 (1.6) 3 (4.8) 42 (87.5) 1 (2.1) 1 (2.1) 3 (6.3) 1 (2.1) Not Hispanic Hispanic Unknown 51 (82.3) 6 (9.7) 5 (8.1) 38 (79.2) 8 (16.7) 2 (4.2) Type I Type II Type III 51 (80.6) 10 (14.5) 1 (4.8) 2 (4.2) 0 0 Previous DKA No previous DKA Unknown 30 (48.4) 29 (46.8) 3 (4.8) – – 2 (4.2) aAge missing for one control patient. bDiabetic ketoacidosis history unavailable for control patients. cPast medical history missing for one control patient. BMI body mass index, DKA diabetic ketoacidosis, CAD coronary artery disease, CHF congestive heart failure, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, AIDS acquired immunodeficiency syndrome, TIA transient ischemic attack, SOFA sequential organ failure assessment Basal respiration The baseline (no treatment) median basal OCR was significantly lower in DKA samples compared to controls (4.7 [3.3, 7.9] vs. 7.9 [5.0, 9.5] pmol/min/μg of protein) (Fig. 1B). With treatment, in DKA samples, there was significant increase in OCRs with all treatments. In the control samples, there was a significant increase in OCR only with thiamine. No significant increase was observed after treatment with CoQ10 or both thiamine and CoQ10 (Fig. 2A). A Mitochondrial respiration profile demonstrating parameters of mitochondrial function in the DKA and control groups. B Comparison of baseline (no treatment) OCR for B Basal, C Maximal, and D ATP-linked. For both basal and maximal OCR, the DKA group had significantly lower OCR compared to the control group Comparison of OCR after treatment between DKA and control groups for A Basal, B Maximal, and C ATP-linked. Changes in OCR after treatment are noted in relation to the baseline OCR (no treatment) for each group Maximal respiration The baseline median maximal OCR was also significantly lower in DKA samples compared to controls (16.4 [9.5, 28.1] vs. 31.5 [20.6, 46.0] pmol/min/μg of protein) (Fig. 1C) With treatment, in DKA samples, there was a significant increase in OCRs with all treatments. In the control samples, there was a significant increase in OCR only when treated with thiamine. No significant increase was observed after treatment with CoQ10 or both thiamine and CoQ10 (Fig. 2B). ATP-linked respiration The baseline median ATP-linked OCR was not significantly different between DKA and controls (4.3 [3.0, 6.9] vs. 6.3 [4.7, 9.2] pmol/min/μg of protein) (Fig. 1D). With treatment, in DKA samples, there was a significant increase in OCRs with all treatments. In the control samples, there was a significant increase in OCR only when treated with thiamine (Fig. 2C). Additional measurements are presented in Tables 2 and 3. Table 2Comparison of Baseline (no treatment) OCR between DKA and control groupsDKA (n = 62)Control (n = 62)Median difference (95% CI)p-valueBasal4.7 (3.3, 7.9)7.9 (5.0, 9.5)− 2.31 (− 4.47, − 0.15)0.036Maximal16.4 (9.5, 28.1)31.5 (20.6, 46.0)− 14.58 (− 20.33, − 8.84)< 0.001 ATP-linked4.3 (3.0, 6.9)6.3 (4.7, 9.2)− 1.60 (− 3.65, 0.45)0.124Spare11.4 (6.1, 21.1)24.9 (13.4, 34.5)− 12.41 (− 17.39, − 7.43)< 0.001Proton leaka0.6 (0.0, 1.1)0.8 (0.0, 1.7)− 0.076 (− 0.80, 0.65)0.834Non-Mitochondrialb2.9 (1.7, 4.2)5.1 (2.6, 6.3)− 1.79 (− 2.68, − 0.90)< 0.001n refers to the number of samples in each group. For the control group, the number of samples (62) was different from the number of patients, since some patients provided samples more than once at different time points. an = 58 (DKAT), n = 59 (Control). bn = 57 (DKAT), n = 57 (Control). OCR is expressed as pmol/min/µg protein and is reported as medians (interquartile range). DKA diabetic ketoacidosis, CI confidence interval, ATP adenosine triphosphate Comparison of Baseline (no treatment) OCR between DKA and control groups n refers to the number of samples in each group. For the control group, the number of samples (62) was different from the number of patients, since some patients provided samples more than once at different time points. an = 58 (DKAT), n = 59 (Control). bn = 57 (DKAT), n = 57 (Control). OCR is expressed as pmol/min/µg protein and is reported as medians (interquartile range). DKA diabetic ketoacidosis, CI confidence interval, ATP adenosine triphosphate Table 3Comparison of OCR with treatmentDKAControlTreatmentOCR (Median, IQR)Relative median difference (%, 95% CI)OCR (Median, IQR)Relative median difference (%, 95% CI)BasalNone4.7 (3.3, 7.9), n = 62–7.9 (5.0, 9.5), n = 62–Thiamine6.1 (3.5, 8.2), n = 6118 (6, 30), p = 0.0058.0 (5.2, 10.7), n = 6016 (3, 29), p = 0.016CoQ106.9 (4.6, 9.4), n = 6037 (19, 55), p < 0.0017.7 (5.2, 10.9), n = 5911 (− 2, 24), p = 0.106Thiamine + CoQ105.9 (3.9, 9.5), n = 6123 (2, 44), p = 0.0347.4 (5.1, 10.5), n = 6214 (− 1, 30), p = 0.064MaximalNone16.4 (9.5, 28.1), n = 62–31.5 (20.6, 46.0), n = 62–Thiamine20.4 (11.2, 33.7), n = 6116 (8, 24), p < 0.00130.9 (22.4, 47.7), n = 6014 (1, 28), p = 0.038CoQ1021.2 (14.4, 30.2), n = 6032 (20, 45), p < 0.00129.9 (19.5, 47.5), n = 58− 6 (− 17, 6), p = 0.356Thiamine + CoQ1022.3 (13.6, 30.7), n = 6124 (6, 42), p = 0.01128.5 (19.4, 47.1), n = 623 (− 13, 19), p = 0.704ATP-linkedNone4.3 (3.0, 6.9), n = 61–6.3 (4.7, 9.2), n = 62–Thiamine5.6 (3.1, 7.6), n = 6019 (8, 30), p = 0.0016.6 (4.5, 10.6), n = 6016 (1, 31), p = 0.039CoQ106.0 (4.1, 8.4), n = 5839 (27, 51), p < 0.0016.0 (4.2, 10.2), n = 581 (− 12, 13), p = 0.918Thiamine + CoQ105.2 (3.3, 7.5), n = 5822 (6, 39), p = 0.0105.7 (4.6, 9.0), n = 610.4 (− 11, 12), p = 0.938SpareNone11.4 (6.1, 21.1), n = 62–24.9 (13.4, 34.5), n = 62–Thiamine13.6 (6.6, 24.3), n = 6121 (11, 31), p < 0.00123.7 (12.8, 38.7), n = 6016 (5, 28), p = 0.006CoQ1014.9 (9.4, 22.6), n = 6046 (27, 65), p < 0.00122.6 (10.2, 36.4), n = 58− 8 (− 19, 3), p = 0.146Thiamine + CoQ1014.5 (8.5, 24.8), n = 6139 (17, 61), p = 0.00122.2 (12.7, 35.2), n = 621 (− 11, 14), p = 0.847Proton leakNone0.6 (0.0, 1.1), n = 58–0.8 (0.0, 1.7), n = 59–Thiamine0.7 (0.3, 1.4), n = 5816 (– + 1223, 1254), p = 0.9800.8 (0.0, 1.9), n = 56− 350 (− 973, 272), p = 0.264CoQ100.9 (0.0, 1.8), n = 57186 (− 511, 884), p = 0.5941.0 (0.4, 2.4), n = 55− 12 (− 228, 204), p = 0.914Thiamine + CoQ100.5 (0.0, 1.4), n = 5752 (− 450, 554), p = 0.8361.0 (0.3, 2.1), n = 59− 15 (− 520, 489), p = 0.951Non-MitoNone2.9 (1.7, 4.2), n = 57–5.1 (2.6, 6.3), n = 57–Thiamine3.6 (2.7, 4.4), n = 5726 (10, 42), p = 0.0023.8 (2.5, 5.0), n = 56− 9 (− 27, 10), p = 0.350CoQ103.9 (2.3, 5.3), n = 5545 (23, 68), p < 0.0014.1 (2.6, 6.0), n = 54− 2 (− 14, 10), p = 0.741Thiamine + CoQ104.5 (2.9, 6.0), n = 5753 (26, 80), p < 0.0014.5 (2.8, 5.8), n = 587 (− 16, 29), p = 0.551OCRs are reported as medians (interquartile ranges). n refers to the number of samples in each group. Relative median difference is the percentage of change relative to baseline values. IQR interquartile range, DKA diabetic ketoacidosis, OCR oxygen consumption rate, Non-mito non-mitochondrial Comparison of OCR with treatment OCRs are reported as medians (interquartile ranges). n refers to the number of samples in each group. Relative median difference is the percentage of change relative to baseline values. IQR interquartile range, DKA diabetic ketoacidosis, OCR oxygen consumption rate, Non-mito non-mitochondrial Differential treatment effect The effect of CoQ10 treatment on basal, maximal, and ATP-linked respiration was significantly greater in samples from patients with DKA than in those from controls. This differential effect was not significant in samples treated with thiamine or the combination of thiamine and CoQ10. Additional results of the interaction analysis are shown in Table 4. Table 4Analysis of interaction between DKA and treatmentTreatmentRelative median difference (%, 95% CI)p-valueBasalThiamine− 0.1 (− 17, 17)0.987CoQ1024 (4, 45)0.020Thiamine + CoQ103 (− 23, 29)0.802MaximalThiamine0.1 (− 17, 18)0.991CoQ1033 (15, 52)0.001Thiamine + CoQ1015 (− 14, 44)0.295ATP-linkedThiamine1 (− 17, 20)0.905CoQ1036 (21, 50)< 0.001Thiamine + CoQ1016 (− 5, 37)0.127SpareThiamine4 (− 12, 21)0.578CoQ1054 (32, 76)< 0.001Thiamine + CoQ1037 (12, 62)0.004Proton leakThiamine380 (− 522, 1282)0.401CoQ1028 (− 393, 449)0.894Thiamine + CoQ1029 (− 574, 633)0.923Non-MitoThiamine33 (9, 57)0.007CoQ1046 (22, 69)< 0.001Thiamine + CoQ1044 (4, 83)0.033The relative median difference is the percentage of change relative to baseline values. CoQ10: Coenzyme Q10; ATP, adenosine triphosphate; Non-mito non-mitochondrial Analysis of interaction between DKA and treatment The relative median difference is the percentage of change relative to baseline values. CoQ10: Coenzyme Q10; ATP, adenosine triphosphate; Non-mito non-mitochondrial Discussion In this study, we found that patients with DKA had impaired mitochondrial function in PMBCs with significantly lower basal, maximal, and ATP-linked respiration compared to healthy controls. We also examined the effect of in vitro thiamine and CoQ10 supplementation on cellular respiration and found that the treatment was generally associated with an increase in respiration. Specifically, in DKA samples, treatment with either thiamine, CoQ10, or both significantly increased basal, maximal, and ATP-linked OCRs. In the control group, only thiamine treatment was associated with a significant increase in OCRs. The overall lower baseline OCRs observed in DKA samples compared to healthy controls are consistent with the hypothesis that mitochondrial function is impaired in DKA. The increase in OCRs observed with thiamine and CoQ10 supplementation in DKA samples provides evidence supporting the hypothesis that treatment with thiamine and CoQ10 could potentially improve mitochondrial function in DKA. CoQ10 treatment increased the OCR in DKA samples to a greater extent than in the controls, and this differential effect was statistically significant. Thiamine treatment increased basal, maximal, and ATP-linked OCRs in both DKA samples and controls. However, there was no differential effect when comparing the effects of thiamine with controls. The underlying reason for the increase in OCR, also seen in controls, is unclear at this time but likely indicates that thiamine can increase the efficiency of aerobic metabolism to some degree, even without deficiency. The differential effect seen in CoQ10 treatment suggests that CoQ10 acts more specifically in the context of DKA, whereas its effect is lower in controls. Further studies are needed to better understand the underlying biochemical mechanisms and the differential treatment effects of CoQ10 compared to thiamine. Mitochondrial dysfunction has been identified as a potential contributor to the pathophysiology of diabetes and its related complications. Mitochondria generate energy for cellular activities via oxidative phosphorylation through various pathways. Dysfunction of these pathways leads to widespread consequences, including impairment in energy production and generation of reactive oxygen species, which have been linked to immune-mediated destruction that characterizes type 1 diabetes, as well as pancreatic islet β-cell dysfunction and insulin resistance in type 2 diabetes [2, 3]. Given that thiamine and CoQ10 are important cofactors required for cellular respiration, deficiencies in these cofactors may contribute to impairment of aerobic respiration and mitochondrial dysfunction in DKA. This study showed significant improvement in OCR with thiamine and CoQ10 supplementation in PMBCs of patients with DKA. To our knowledge, this is the first study to evaluate changes in mitochondrial respiration with in vitro thiamine and CoQ10 supplementation. These findings provide further evidence to support the hypothesis that (1) mitochondrial function and aerobic respiration are depressed in DKA, and (2) aerobic respiration can potentially be improved by treatment with thiamine and CoQ10. Although these findings are promising, it should be noted that this was a preliminary study and hypothesis generating. The results of this study should be interpreted within the context of several limitations. First, this study evaluated in vitro thiamine and CoQ10 treatment and, therefore, further studies are needed to assess their effects in vivo. Second, OCRs were measured in PBMCs, and whether the findings will translate to other cell types is unclear. A randomized clinical trial of thiamine administration in DKA is currently ongoing, and may answer some of these questions, including exploring the effect of intravenous thiamine on cellular OCR (ClinicalTrial.Gov, NCT03717896). Third, we did not measure baseline thiamine and CoQ10 levels in the context of this study; therefore, we do not know if the treatment effect is due to deficiencies in these substrates or due to the metabolic cellular environment in the setting of DKA. Conclusion Mitochondrial metabolic profiles of patients with DKA demonstrated lower cellular oxygen consumption when compared to healthy controls. Oxygen consumption increased significantly in cells of patients with DKA treated with thiamine and/or CoQ10. These results suggest that thiamine and CoQ10 could potentially have therapeutic benefits in DKA via their metabolic effects on mitochondrial cellular respiration. Acknowledgements The authors would like to acknowledge the Center for Resuscitation Science research staff at Beth Israel Deaconess Medical Center, Boston, USA. Abbreviations Adenosine triphosphate Coenzyme Q10 Diabetic ketoacidosis Institutional review board Linear quantile mixed model Oxygen consumption rate Peripheral blood mononuclear cell Pyruvate dehydrogenase Author contributions All authors contributed substantially to this work. JV, JHL, AnM, XL drafted the initial manuscript. AnM, NA, NP, XL contributed to the acquisition of specimens and conducted the experiments. AVG and LB performed the statistical analysis. JV, JHL, AVG, LB, KB, ArM, MWD, XL interpreted the data. NB, MSK, SBL, KB, ArM revised the manuscript for intellectual content. MWD and XL conceptualized, designed and supervised the study. All authors reviewed and approved the final manuscript. Funding This work was supported by the National Institute of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (Grant number 1R01DK112886-01A1). JV, JHL, MSK, SBL, NB are supported by the National Heart, Lung, and Blood Institute grant (T32HL155020). MWD is supported, in part, by the National Heart, Lung, and Blood Institute grant (K24HL127101). Availability of data and materials The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The study was approved by the Beth Israel Deaconess Medical Center local institutional review board (IRB) (protocol no. 2018P000475), and written informed consent was obtained from each patient prior to enrollment. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Jacob Vine and John H. Lee are co-first authors. References Associated Data Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.